An open-label pilot study of dose escalation of PEGASYS [peginterferon alfa-2a] on virological response in patients with chronic hepatitis C viral infection showing an early non-response to a standard course of PEGASYS plus ribavirin.
Phase of Trial: Phase III
Latest Information Update: 10 Jun 2016
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms PINGU
- Sponsors Roche
- 06 Jun 2016 Study phase changed form phase 2 to phase 3
- 06 Jun 2016 Status changed from completed to discontinued.
- 23 Feb 2010 Status changed from active, no longer recruiting to completed as reported by Roche record.